Overview

Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks
Phase:
Phase 4
Details
Lead Sponsor:
Yonsei University
Collaborator:
Roche Pharma AG
Treatments:
Interferon-alpha
Interferons
Peginterferon alfa-2a